Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin [Yahoo! Finance]
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: Yahoo! Finance
Repligen (NASDAQ:RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executive Officer Olivier said he has been with the company about two and a half years and has served as CEO for roughly a year and a half, adding that he is “more excited than ever” about the company's positioning in bioprocessing. Portfolio breadth and “differentiated” products Olivier emphasized that innovation remains central to Repligen's approach, describing an effort to help customers improve yields and reduce manufacturing costs. In response to a question about differentiation across the portfolio, he said roughly 80% of the company's products are differentiated, driven by research and development aimed at solving unmet customer needs. ? Forget Chipmakers: Walmart and Target Are the Real AI Plays He highlighted two examples: ATF (a process intensification technology): Olivier
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- Repligen (RGEN) had its price target raised by HC Wainwright from $180.00 to $208.00. They now have a "buy" rating on the stock.MarketBeat
- Repligen Earnings Beat Puts Focus On Analytics Growth And Rich Valuation [Yahoo! Finance]Yahoo! Finance
- A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack [Yahoo! Finance]Yahoo! Finance
- 2 Growth Stocks Set to Flourishand 1 We Turn Down [Yahoo! Finance]Yahoo! Finance
- Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
RGEN
Earnings
- 2/24/26 - Beat
RGEN
Sec Filings
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- RGEN's page on the SEC website